New research reveals how immune cells, hormones, sensory neurons, and the biology of pain resolution may help explain why pain persists
Biotech International Institute (BII)
The Hidden Biology of the Brain — Wednesday, October 28, 2026
Introduction: Why Does Pain Disappear for Some People but Persist for Others?
Pain is one of the nervous system's most important protective mechanisms.
It alerts us to injury, inflammation, and potentially harmful conditions.
Following an injury, pain sensitivity may increase as the body begins responding to tissue damage.
As healing progresses, pain often decreases.
But that process does not happen equally for everyone.
Some individuals recover quickly.
Others continue experiencing pain for months or years.
And across several chronic pain conditions, women experience a higher burden of symptoms than men.
For decades, scientists have recognized these differences.
But a fundamental question has remained:
Why does pain resolve more readily in some people while remaining persistent in others?
Traditionally, much of pain research focused on how pain begins.
Researchers investigated sensory receptors, injured nerves, inflammatory molecules, and the pathways that transmit pain signals to the brain.
More recently, scientists have begun asking a different question.
What biological mechanisms actively help pain stop?
This shift is important.
Pain resolution may not simply occur when inflammation disappears or damaged tissue heals.
It may also depend on active communication between immune cells, sensory neurons, hormones, and other biological systems.
New research published in 2026 provides fascinating evidence for this possibility.
At Biotech International Institute, these discoveries are relevant to our broader scientific interests in neuroimmune signaling, cannabinoid receptor biology, and non-opioid pain research.
But understanding their significance begins with the biology of pain itself.
---
1. Pain Is More Than a Signal From an Injured Nerve
Pain begins with specialized sensory systems that detect potentially damaging conditions.
A major class of sensory neurons is known as nociceptors.
These neurons respond to harmful mechanical, thermal, or chemical stimuli.
Their signals travel through peripheral nerves and spinal pathways to networks involved in pain perception.
But pain is not simply a direct measurement of tissue damage.
The brain integrates sensory information with attention, previous experience, emotional state, and biological context.
This helps explain why pain intensity does not always correspond directly to the severity of an injury.
Following tissue damage, inflammatory mediators can increase nociceptor sensitivity.
This process may produce heightened pain responses.
During normal recovery, sensitivity often decreases.
However, in chronic pain, altered signaling can persist.
In some conditions, changes occur in peripheral nerves.
In others, spinal and brain circuits become involved.
Immune signaling can contribute to these changes.
Understanding chronic pain therefore requires studying interactions among multiple biological systems.
2. What Makes Pain Chronic?
Chronic pain is generally described as pain that persists or recurs for more than three months.
It can develop following injury, surgery, inflammation, or disease.
It can also occur without a clearly identifiable ongoing tissue injury.
Researchers often distinguish among three broad categories.
Nociceptive pain
Pain associated with actual or threatened damage to non-neural tissues and activation of nociceptors.
Neuropathic pain
Pain caused by a lesion or disease affecting the somatosensory nervous system.
Nociplastic pain
Pain arising from altered nociception despite the absence of clear evidence that ongoing tissue damage or a somatosensory lesion fully explains the experience.
These categories can overlap.
A person may have several contributing mechanisms.
This complexity makes chronic pain difficult to treat.
It also raises questions about whether people with similar symptoms may have different underlying biological mechanisms.
3. Why Sex Differences Matter in Pain Research
Women experience a higher prevalence of several chronic pain conditions.
Examples include fibromyalgia, migraine, irritable bowel syndrome, and certain musculoskeletal pain disorders.
But biological sex is not the only factor that influences pain.
Hormonal state, genetics, age, immune function, previous injuries, medications, social context, and access to healthcare can also affect pain experiences and outcomes.
Historically, many experimental pain studies relied heavily on male laboratory animals.
This limited understanding of biological mechanisms that might differ between sexes.
Increasing recognition of this problem has encouraged researchers to investigate sex as an important biological variable.
An October 2026 review in Science, titled Sex-specific mechanisms of chronic pain, examines emerging evidence that different cellular and molecular pathways may contribute to the initiation, amplification, and resolution of pain.
The review emphasizes several interacting mechanisms:
- Sex hormones
- Immune-neural communication
- Gut microbiome interactions
- Endogenous pain-modulating systems
- Peripheral and central nervous system signaling
An important scientific implication is that different biological pathways may sometimes produce similar pain-related outcomes.
However, average differences between research groups do not mean every woman or man experiences pain through the same mechanism.
Individual variability remains substantial.
4. The Immune System May Help Determine How Long Pain Lasts
One of the most interesting developments in pain research involves the relationship between immune cells and sensory neurons.
Immune cells are traditionally associated with infection, inflammation, and tissue repair.
But certain immune populations can also influence nociceptor activity.
Some inflammatory molecules increase pain sensitivity.
Others may contribute to the resolution of pain.
A major question is whether differences in immune signaling help explain why pain lasts longer in certain individuals.
In February 2026, researchers led by Geoffroy Laumet at Michigan State University published a study in Science Immunology examining this question.
The study focused on a particular type of immune cell known as a monocyte.
It also investigated an anti-inflammatory signaling molecule called interleukin-10, or IL-10.
The results provide evidence that immune cells may participate directly in actively reducing pain sensitivity.
5. The 2026 Discovery: Monocytes May Help Switch Off Pain
Monocytes are immune cells that circulate in the blood and can participate in responses to tissue injury and inflammation.
Some monocytes produce IL-10.
IL-10 is a cytokine involved in regulating immune responses.
In the 2026 study, researchers investigated whether IL-10-producing monocytes influenced how quickly pain sensitivity resolved.
Using mouse models of inflammatory pain and traumatic injury, they observed that male mice generally recovered from pain sensitivity faster than female mice under the tested conditions.
Interestingly, the difference was not explained simply by greater initial inflammation in the female animals.
Instead, male mice showed higher levels of IL-10 in affected tissue and more IL-10-producing monocytes in the relevant experimental setting.
The researchers then performed experiments designed to test whether these immune cells were causally involved.
When monocyte populations were reduced, pain sensitivity persisted longer.
When monocytes were unable to produce IL-10, pain resolution was impaired.
And when sensory neurons lacked the relevant IL-10 receptor component, pain resolution was also delayed.
These findings suggest that IL-10-producing monocytes contribute to the active resolution of pain in the models studied.
The important discovery is not simply that inflammation affects pain.
It is that a particular immune-cell signaling pathway may help determine when pain ends.
6. How IL-10 Communicates With Sensory Neurons
One of the most scientifically significant aspects of the study was the relationship between IL-10 and nociceptors.
The researchers found evidence that IL-10 signaling influenced sensory neurons through an IL-10 receptor pathway.
When the relevant receptor function was disrupted in sensory neurons, normal pain resolution was impaired.
This suggests that the immune system may influence pain duration through direct communication with sensory pathways.
That is an important concept.
An immune signal can affect more than immune cells.
It can also influence the activity of neurons involved in detecting pain.
This creates a biological link between immune regulation and sensory function.
However, IL-10 has multiple biological roles.
Increasing IL-10 everywhere in the body would not necessarily produce the same effect as selectively modifying a defined signaling pathway in a specific tissue.
Any potential therapeutic strategy would need to consider dose, location, timing, biological effects, and safety.
7. Hormones May Influence Pain Resolution
The researchers also investigated whether sex hormones contributed to differences in IL-10-producing monocytes.
In their experiments, androgen signaling helped regulate the abundance and activity of relevant immune cells.
This provided one possible mechanism for differences in pain duration between male and female mice.
But this does not establish that testosterone alone determines pain recovery in humans.
Hormonal biology is complex.
Different hormones can affect immune function, sensory neurons, and other systems through multiple pathways.
Hormone levels also vary throughout life.
Researchers therefore need to distinguish between experimentally observed mechanisms in controlled animal models and the broader biological variation seen in people.
The study supports a relationship among androgen signaling, IL-10-producing monocytes, and pain resolution under the investigated conditions.
It does not provide a basis for recommending hormone treatment for chronic pain.
8. What Did the Researchers Find in Humans?
The study did not rely exclusively on mouse experiments.
Researchers also examined information from 245 individuals who had experienced traumatic injuries.
Pain severity was similar between men and women shortly after injury.
But after 12 weeks, the men in this study reported less pain on average than the women.
The investigators also observed associations involving circulating monocytes and IL-10.
Higher levels of these measures were associated with less pain at the later time point.
This supports the relevance of the immune-signaling hypothesis to human pain recovery.
However, the human findings were observational.
They do not independently prove that modifying IL-10 levels will prevent chronic pain in patients.
Further research would be necessary to establish whether targeted interventions are effective and safe.
9. Another Important Finding: Not All Immune Cells Affect Pain the Same Way
Immune regulation involves many specialized cell populations.
Monocytes are only one example.
Researchers have also studied macrophages, microglia, regulatory T cells, and other immune populations in pain-related biology.
Different populations may contribute through different mechanisms.
Some immune responses increase pain sensitivity.
Others may reduce inflammation or help restore normal sensory signaling.
In April 2025, NIH highlighted research showing that regulatory T cells could influence pain sensitivity in a sex-dependent manner in mice.
This provides another example of how immune cells may participate in pain modulation.
But the mechanisms should not be combined into one simplified explanation.
Regulatory T cells and monocytes have different biological functions.
The tissues, models, and signaling pathways involved can differ.
Understanding those distinctions is essential for future research.
10. What About Microglia and the Spinal Cord?
Microglia are specialized resident immune cells of the central nervous system.
They have been investigated extensively in experimental pain research, particularly in the spinal cord.
Some rodent studies have identified sex-dependent contributions of microglial and immune signaling pathways to pain hypersensitivity.
However, these findings are highly dependent on experimental models and biological context.
They should not be simplified into the claim that chronic pain in men is exclusively driven by microglia while chronic pain in women is exclusively driven by T cells.
Human pain biology is considerably more complicated.
The emerging scientific perspective is that multiple immune-neural pathways can influence pain, and their relative importance may vary across individuals and conditions.
11. Could Pain Resolution Become a New Drug-Discovery Target?
Historically, many analgesic approaches have focused on reducing pain signals after they arise.
The emerging science of pain resolution suggests another possible direction.
Instead of only blocking pain signaling, researchers might investigate mechanisms that help the nervous system return toward normal sensitivity.
This is an important scientific distinction.
Pain inhibition and pain resolution may involve overlapping but different biological pathways.
The 2026 IL-10 study identified an immune-neural mechanism that contributed to resolution in experimental models.
The investigators also examined a compound that increased IL-10-producing monocytes.
In their mouse experiments, this approach accelerated pain resolution under conditions where the relevant IL-10 mechanism remained functional.
These findings suggest a possible research direction for future non-opioid therapies.
But they do not establish that the intervention is effective in humans.
Nor do they demonstrate that the same strategy applies to all forms of chronic pain.
12. Why the Gut Microbiome Is Entering the Conversation
The October 2026 Science review also discusses the gut microbiome as one of several potential contributors to sex-related differences in pain biology.
The microbiome interacts with immune function, metabolism, and other physiological systems.
Researchers are investigating whether microbiome-related differences influence inflammatory and sensory pathways.
However, the direction of causality is not always clear.
Microbiome differences may contribute to biological processes.
They may also reflect diet, medications, health conditions, and other factors.
Finding an association between microbial composition and pain does not establish that changing particular microbes will improve pain outcomes.
This remains an active area of research.
13. What Does This Mean for Women's Health?
The emerging science has implications for women's health research.
For decades, women have experienced a substantial burden of chronic pain disorders.
Yet the specific biological mechanisms contributing to those differences have not always received sufficient research attention.
Recognizing sex-related differences can help investigators design better studies.
It may improve understanding of disease mechanisms, identify additional experimental targets, and encourage more representative research.
But responsible science must also avoid oversimplification.
Sex-related biological differences do not eliminate the importance of individual physiology, environment, clinical history, or social influences.
The goal is not to treat women and men as two uniform biological categories.
It is to understand which mechanisms matter for which patients.
14. Neurophorol™ and BII's Interest in Neuroimmune Signaling
At Biotech International Institute, Neurophorol™ represents our research-stage CB2-oriented cannabinoid small-molecule platform.
Its proposed scientific focus includes receptor pharmacology, neuroimmune signaling, and inflammation-related biological mechanisms.
The emerging relationship between immune cells and pain resolution provides scientific context for why receptor-specific and immune-neural research may be important.
But several questions must be kept separate.
Does a defined candidate interact with CB2?
Does that interaction change relevant immune-cell activity?
Are any observed biological effects linked to sensory signaling?
Do those effects depend on dose, tissue, biological context, or sex-related variables?
Are they reproducible?
Are they safe under appropriate experimental conditions?
BII has not demonstrated that Neurophorol™ modifies IL-10 signaling, accelerates pain resolution, relieves chronic pain, or provides clinical benefit.
The IL-10 findings discussed here were obtained using other experimental interventions and should not be attributed to Neurophorol™.
They illustrate a broader principle:
Immune-neural communication may be an important research direction for understanding why pain persists or resolves.
15. BII's Broader Interest in Non-Opioid Pain Research
BII also maintains scientific interests involving pain-related research beyond Neurophorol™.
Pain biology may involve peripheral nerves, spinal circuits, immune signaling, neuroplasticity, and other interacting systems.
These mechanisms create opportunities for investigating different molecular approaches.
However, potential therapies must be evaluated individually.
A promising receptor hypothesis does not establish analgesic efficacy.
A change in an inflammatory biomarker does not demonstrate meaningful pain relief.
And results from one experimental model may not translate directly to other pain conditions.
For BII, responsible small-molecule research requires defined targets, appropriate models, independent evaluation, and careful safety assessment.
16. What Scientists Still Need to Discover
Despite recent advances, major questions remain.
Do IL-10-producing monocytes influence pain resolution across different human pain conditions?
Can researchers identify patients whose pain persists because of particular immune-signaling differences?
How do hormones, age, genetics, and immune history modify those responses?
Do similar mechanisms operate in neuropathic and nociplastic pain?
Could targeted immune-neural interventions reduce persistent pain without disrupting essential immune functions?
How do peripheral immune signals interact with spinal and brain circuits?
And can findings from experimental models lead to safe, effective non-opioid treatments?
These questions represent important opportunities for future research.
Closing Thought: What If Understanding How Pain Ends Is as Important as Understanding How It Begins?
Pain science has made important progress in identifying how sensory signals are generated, transmitted, and amplified.
But recent research suggests that the resolution of pain may also depend on active biological processes.
Immune cells may help regulate sensory neurons.
Hormonal signaling may influence those immune responses.
And the mechanisms governing pain persistence may differ across biological contexts.
The discovery of IL-10-producing monocytes as contributors to pain resolution in experimental models provides an important new direction for investigation.
For Biotech International Institute, these findings reinforce our broader scientific interest in neuroimmune communication and non-opioid pain research.
They do not establish clinical effects for any BII investigational platform.
The goal is to understand what the science actually demonstrates and use that knowledge to frame responsible research questions.
Perhaps one of the next major advances in pain science will come not from discovering another way to suppress pain, but from understanding the biological processes that allow pain to resolve.
That is a question worth investigating.
Research-stage. Built for validation.
Mechanism first. Validation always.
Biotech International Institute
Science. People. Communities. A Healthier Tomorrow.
---
Scientific References
1. Venkataraman, A., Midavaine, É., & Ingraham, H. A. (2026).
Sex-specific mechanisms of chronic pain.
Science, 394(6819), 69–74. Published October 1, 2026.
https://doi.org/10.1126/science.aeh4468
2. Sim, J., et al. (2026).
Monocyte-derived IL-10 drives sex differences in pain duration.
Science Immunology, 11(116), eadx0292. Published February 20, 2026.
https://doi.org/10.1126/sciimmunol.adx0292
3. National Institutes of Health (2026).
Immune cells may underlie sex differences in chronic pain.
NIH Research Matters, March 10, 2026.
https://www.nih.gov/news-events/nih-research-matters/immune-cells-may-underlie-sex-differences-chronic-pain
4. Brezic, N., et al. (2026).
Sexually Dimorphic Neuroimmune Pathways in Chronic Pain: A Comprehensive Systematic Review of Cellular and Molecular Mechanisms.
Biomolecules, 16(2), 258.
https://doi.org/10.3390/biom16020258
5. National Institutes of Health (2025).
Sex-specific pain suppression by immune cells.
NIH Research Matters, April 15, 2025.
https://www.nih.gov/news-events/nih-research-matters/sex-specific-pain-suppression-immune-cells
Research disclosure: This article discusses findings from published clinical, observational, and experimental studies. Neurophorol™ and BII's other pain-related research directions remain investigational. No claims of established analgesic efficacy, IL-10 modulation, safety, or clinical treatment benefit are being made.
